Amerikanische Gesellschaft für Hirudotherapie

Tyrosine-O-sulfation is a widespread affinity enhancer among thrombin interactors

Structural biology published in Biochemical Society Transactions (2022)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Speichel-PharmakologieArzneimittelentwicklungRipoll-Rozada J et al. · Biochemical Society transactions, 2022

Abstract

Tyrosine-O-sulfation is a common post-translational modification (PTM) of proteins following the cellular secretory pathway. First described in human fibrinogen, tyrosine-O-sulfation has long been associated with the modulation of protein-protein interactions in several physiological processes. A number of relevant interactions for hemostasis are largely dictated by this PTM, many of which involving the serine proteinase thrombin (FIIa), a central player in the blood-clotting cascade. Tyrosine sulfation is not limited to endogenous FIIa ligands and has also been found in hirudin, a well-known and potent thrombin inhibitor from the medicinal leech, Hirudo medicinalis. The discovery of hirudin led to successful clinical application of analogs of leech-inspired molecules, but also unveiled several other natural thrombin-directed anticoagulant molecules, many of which undergo tyrosine-O-sulfation. The presence of this PTM has been shown to enhance the anticoagulant properties of these peptides from a range of blood-feeding organisms, including ticks, mosquitos and flies. Interestingly, some of these molecules display mechanisms of action that mimic those of thrombin's bona fide substrates.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAnimalsAnticoagulantsHirudinsThrombinTyrosine

Zusammenfassung

Review of tyrosine-O-sulfation as broad affinity enhancer for thrombin interactors including hirudin — key structural biology for leech-derived inhibitor design.

Warum dies für die Hirudotherapie relevant ist

This article discusses tyrosine-O-sulfation as a post-translational modification associated with the modulation of protein-protein interactions in several physiological processes, including hemostasis, with specific attention to thrombin-directed anticoagulants. It notes that hirudin, a potent thrombin inhibitor from Hirudo medicinalis, undergoes tyrosine-O-sulfation, and that the discovery of hirudin led to clinically applied leech-inspired analogs. The abstract states that tyrosine-O-sulfation has been shown to enhance the anticoagulant properties of peptides from ticks, mosquitos, and flies, and that some of these molecules mimic thrombin's substrates. For ASH's domain, this work contextualizes hirudin within a broader landscape of thrombin inhibitors and PTM-mediated affinity enhancement, though the abstract does not explicitly attribute enhanced potency to sulfated hirudin itself and does not specify the study design.

Zitation

Tyrosine-O-sulfation is a widespread affinity enhancer among thrombin interactors.

Ripoll-Rozada J et al. · Biochemical Society transactions, 2022

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.